After completing a Ph.D. in reproductive toxicology at Edinburgh University in the UK, Gary post-doc’ed at Hoffmann La Roche in the U.S.A, studying the pharmacology of retinoid biology and examining retinoid receptor binding. He returned to the U.K. in 1995 to join the Lead Generation group at Glaxo Wellcome, developing cell-based ion channel and GPCR assays for high throughput screening and working with vendors to validate new technologies for screening and automating cell-based assay for HTS. In 2000, he joined the Hit Identification group at AstraZeneca, developing assays for respiratory and inflammatory disease and continuing to work with vendors on new technology and to automate assays. In 2011, he co-founded Aurelia Bioscience, a pre-clinical contract research organisation based in Nottingham, U.K. Aurelia Bioscience focuses on the development and implementation of innovative cell-based assays for compound profiling and screening purposes for clients and collaborating with vendors to deliver value adding data for drug discovery purposes.
